Literature DB >> 25790909

Antiproliferative activity of the isoindigo 5'-Br in HL-60 cells is mediated by apoptosis, dysregulation of mitochondrial functions and arresting cell cycle at G0/G1 phase.

Ayman M Saleh1, Mustafa M El-Abadelah2, Mohammad Azhar Aziz3, Mutasem O Taha4, Amre Nasr5, Syed A A Rizvi6.   

Abstract

Our new compound, 5'-Br [(E)-1-(5'-bromo-2'-oxoindolin-3'-ylidene)-6-ethyl-2,3,6,9-tetrahydro-2,9-dioxo-1H-pyrrolo[3,2-f]quinoline-8-carboxylic acid], had shown strong, selective antiproliferative activity against different cancer cell lines. Here, we aim to comprehensively characterize the mechanisms associated with its cytotoxicity in the human promyelocytic leukemia HL-60 cells. We focused at studying the involvement of apoptotic pathway and cell cycle effects. 5'-Br significantly inhibited proliferation by inducing caspase-dependent apoptosis. Involvement of caspase independent mechanism is also possible due to observed inability of z-VAD-FMK to rescue apoptotic cells. 5'-Br was found to trigger intrinsic apoptotic pathway as indicated by depolarization of the mitochondrial inner membrane, decreased level of cellular ATP, modulated expression and phosphorylation of Bcl-2 leading to loss of its association with Bax, and increased release of cytochrome c. 5'-Br treated cells were found arrested at G0/G1 phase with modulation in protein levels of cyclins, dependent kinases and their inhibitors. Expression and enzymatic activity of CDK2 and CDK4 was found inhibited. Retinoblastoma protein (Rb) phosphorylation was also inhibited whereas p21 protein levels were increased. These results suggest that the antiproliferative mechanisms of action of 5'-Br could involve apoptotic pathways, dysregulation of mitochondrial functions and disruption of cell cycle checkpoint.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Anticancer; Apoptosis; CDK; Cell cycle; Isoindigo; Mitochondria dysfunction

Mesh:

Substances:

Year:  2015        PMID: 25790909     DOI: 10.1016/j.canlet.2015.03.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Effect of cell cycle synchronization on cadmium-induced apoptosis and necrosis in NRK-52E cells.

Authors:  Tongwang Luo; Qi Yu; Wenxuan Dong; Zhonggui Gong; Yun Tan; Wenjing Liu; Hui Zou; Jianhong Gu; Yan Yuan; Jianchun Bian; Chunyan Shao; Jiaqiao Zhu; Zongping Liu
Journal:  Cell Cycle       Date:  2020-11-23       Impact factor: 4.534

2.  RNF135, RING finger protein, promotes the proliferation of human glioblastoma cells in vivo and in vitro via the ERK pathway.

Authors:  Yongjian Liu; Feng Wang; Yongsheng Liu; Yiqun Yao; Xiupeng Lv; Bin Dong; Jun Li; Siyang Ren; Yiwen Yao; Yinghui Xu
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

3.  In vitro assessment of anti-proliferative effect induced by α-mangostin from Cratoxylum arborescens on HeLa cells.

Authors:  Aisha I El Habbash; Najihah Mohd Hashim; Mohamed Yousif Ibrahim; Maizatulakmal Yahayu; Fatima Abd Elmutaal Omer; Mashitoh Abd Rahman; Noraziah Nordin; Gwendoline Ee Cheng Lian
Journal:  PeerJ       Date:  2017-07-21       Impact factor: 2.984

4.  Nanoscale isoindigo-carriers: self-assembly and tunable properties.

Authors:  Tatiana N Pashirova; Andrei V Bogdanov; Lenar I Musin; Julia K Voronina; Irek R Nizameev; Marsil K Kadirov; Vladimir F Mironov; Lucia Ya Zakharova; Shamil K Latypov; Oleg G Sinyashin
Journal:  Beilstein J Nanotechnol       Date:  2017-02-01       Impact factor: 3.649

5.  The genetically engineered drug rhCNB induces apoptosis via a mitochondrial route in tumor cells.

Authors:  Yang Yang; Huan Yang; Jinju Yang; Li Li; Benqiong Xiang; Qun Wei
Journal:  Oncotarget       Date:  2017-07-22

6.  Inhibition of human prostate cancer (PC-3) cells and targeting of PC-3-derived prostate cancer stem cells with koenimbin, a natural dietary compound from Murraya koenigii (L) Spreng.

Authors:  Behnam Kamalidehghan; Soudeh Ghafouri-Fard; Elahe Motevaseli; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2018-05-04       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.